Adelle Diagnostics develops AI-based platforms for biomarker identification and blood-based diagnostic tests targeting neurodegenerative diseases, including normal pressure hydrocephalus. The company uses molecular technologies combined with data analysis to support accurate diagnosis and predict treatment outcomes, such as shunt surgery benefits.